FDA Requests More Data After Reviewing IsoRay’s Application for GammaTile Radiation Therapy July 12, 2017 IsoRay, a company specializing in the treatment of prostate and other cancers, has received a response from the U.S. Food and Drug Administration (FDA) regarding the company’s pending 510(k) application for its GammaTile radiation therapy system.Read more.Source: Prostate Cancer News Today Prostate Cancer News
IsoRay, a company specializing in the treatment of prostate and other cancers, has received a response from the U.S. Food and Drug Administration (FDA) regarding the company’s pending 510(k) application for its GammaTile radiation therapy system.Read more.Source: Prostate Cancer News Today
Complete the Survey
